LCM
UBX

Laurion Capital Management’s Unity Biotechnology UBX Stock Holding History

Laurion Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-21,569
Closed -$41.6K – 635
2023
Q4 		$41.6K Sell
21,569
-48,431
-69% -$90.1K ﹤0.01% 455
2023
Q3 		$168K Hold
70,000
– – ﹤0.01% 432
2023
Q2 		$179K Hold
70,000
– – ﹤0.01% 493
2023
Q1 		$114K Hold
70,000
– – ﹤0.01% 399
2022
Q4 		$192K Hold
70,000
– – ﹤0.01% 384
2022
Q3 		$277K Buy
+70,000
New +$441K ﹤0.01% 425
2018
Q3 		– Sell
-12,795
Closed -$1.93M – 1545
2018
Q2 		$1.93M Buy
+12,795
New +$1.87M 0.02% 617

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Laurion Capital Management's UBX Position: Q1 2024 in Review

Laurion Capital Management sold out of Unity Biotechnology (UBX) in Q1 2024, closing a stake of 21,569 shares — an estimated $41.6K sold.

Laurion Capital Management first reported a position in UBX in Q2 2018 and held it in 7 quarters. The position peaked at $1.93M in Q2 2018. 40 funds tracked by Wall St. Rank hold UBX as of Q1 2024.

  • Laurion Capital Management reported no remaining Unity Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Laurion Capital Management sold 21,569 Unity Biotechnology shares in Q1 2024, an estimated $41.6K.
  • Laurion Capital Management first reported a position in Unity Biotechnology in Q2 2018 and held it in 7 quarters.
  • Laurion Capital Management's Unity Biotechnology position peaked at $1.93M in Q2 2018.
  • 40 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2024.

Based on Laurion Capital Management's 13F filing for Q1 2024, filed 15 May 2024.